DATASHEET
Host:
Rabbit
Target Protein:
NFkB p105/p50
Clonality:
Recombinant
Isotype:
IgG
Entrez Gene:
4790
Swiss Prot:
P19838
Source:
Recombinant human NFkB p105/ p50 between 300 to 400 amino acids
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage:
Store at -20°C for 12 months.
Background:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally.
PRODUCT SPECIFIC PUBLICATIONS
- Yong Wei. et al. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer. AGING-US. 2024 Mar 31; 16(6): 5387C5411Read more>>
VALIDATION IMAGES
Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed and paraffin-embedded Mouse bladder tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Lane 1: Human Raji cell lysates; Lane 2: Human MCF-7 cell lysates; Lane 3: Human Jurkat cell lysates; Lane 4: Human A431 cell lysates; Lane 5: Human HeLa cell lysates probed with NFKB1 Monoclonal Antibody, Unconjugated (bsm-52309R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.